All Substitutes
Loading...
Disclaimer
Did you find this information helpful?
Tromlieva 25mg Tablet 7'S
Prescription Required
Salt Composition : Eltrombopag
Manufacturer : Allieva Pharma Pvt. Ltd.
Origin of Medicine : India
7 Tablet(s) In A Strip
Introduction to Tromlieva 25mg Tablet 7's
Tromlieva 25mg Tablet 7'S is an anticoagulant drug belonging to the thrombopoietin (TPO) receptor agonist category, containing the active ingredient Eltrombopag. It is used to treat low platelet counts caused by primary immune thrombocytopenia (ITP) or hepatitis C (HCV) infection. ITP is an autoimmune disorder where the immune system destroys platelets, which are blood cells essential for clotting and protecting blood vessel walls. Low platelet levels can lead to severe bleeding and bruising. This tablet is also indicated for treating adults with severe aplastic anemia, a serious condition where the bone marrow fails to produce sufficient new blood cells.
This drug should not be used in individuals with known hypersensitivity or allergic reactions to the medication or its components. Allergic reactions can range from mild to severe and include symptoms like rash, itching, swelling, dizziness, or difficulty breathing. Tromlieva 25mg Tablet 7'S is contraindicated in patients with severe liver impairment or active liver disease, as it may cause hepatotoxicity (liver damage), indicated by increased liver enzymes and bilirubin levels. Patients should be monitored closely to avoid further liver function deterioration. Your doctor may also check for cataracts or bleeding in or around the retina (the light-sensitive layer at the back of the eye).
Uses of Tromlieva 25mg Tablet 7's
Tromlieva 25mg Tablet 7'S is used to treat:
- Low platelet counts caused by primary immune thrombocytopenia (ITP) or hepatitis C virus (HCV) infection.
- Severe aplastic anemia.
Therapeutic Effects of Tromlieva 25mg Tablet 7's
Tromlieva 25mg Tablet 7'S stimulates megakaryocytes (large bone marrow cells responsible for producing platelets). By increasing the platelet count, this drug helps prevent bleeding and bruising.
Interaction of Tromlieva 25mg Tablet 7's with other drugs
Inform your healthcare provider about all medications you are taking, including prescription, over-the-counter, nutritional or vitamin supplements, and herbal products. Certain medicines, such as antacids, statins, ciclosporin, methotrexate, topotecan, lopinavir, ritonavir, and vitamin or mineral supplements, may interact with Tromlieva 25mg Tablet 7'S, reducing its effectiveness or causing side effects.
More Information about Tromlieva 25mg Tablet 7's
If you stop taking this tablet, your platelet count may drop again within a few days. Regular monitoring of platelet levels is essential, and your doctor will advise on necessary precautions. A very high platelet count can increase the risk of blood clot formation, though clots can also form at normal or low platelet counts.
How to consume Tromlieva 25mg Tablet 7's
This is an orally available prescription drug. Your doctor will determine the dose and duration of the drug based on your condition. Always take Tromlieva 25mg Tablet 7'S as prescribed. It can be taken with or without food, but do not chew, crush, or break the tablet. Swallow it whole with water.
Safety Advices for Tromlieva 25mg Tablet 7's
Pregnancy
Tromlieva 25mg Tablet 7'S is not recommended during pregnancy as it may harm the fetus. Inform your doctor if you are pregnant, suspect you may be, or plan to become pregnant during treatment.
Breast Feeding
It is unclear whether this drug passes into breast milk. If you are breastfeeding or planning to, consult your doctor.
Lungs
The effect of this medication on patients with lung problems is unknown. Consult your doctor if you have any lung conditions.
Liver
Patients with severe liver conditions should use this medication cautiously. Dose adjustments may be necessary. Inform your doctor about any liver issues before starting treatment.
Alcohol
The interaction between Tromlieva 25mg Tablet 7'S and alcohol is not well established. Discuss alcohol consumption with your doctor.
Driving
Avoid driving or operating heavy machinery after taking Tromlieva 25mg Tablet 7'S, as it may cause dizziness and impair concentration.
Side Effects of Tromlieva 25mg Tablet 7's
Common side effects include:
- Nausea
- Diarrhea, abdominal pain
- Common cold
- Cough
- Respiratory tract infection
- Back pain
- Fever
- Loss of appetite
- Hair loss
- Swelling in feet or hands
- Headache, dizziness
- Mouth and throat pain
- Joint pain
Word of Advice
Avoid consuming dairy products, antacids, or supplements containing iron, calcium, magnesium, aluminum, selenium, or zinc within 2 hours after or 4 hours before taking this medication, as these can interfere with its absorption. If you miss a dose, take your next dose at the usual time but do not double the dose. Do not stop taking the tablet without consulting your doctor. Your platelet count will be monitored for four weeks after stopping treatment.
FAQs
Q 1. What is ITP?
Immune thrombocytopenia (ITP) is a rare autoimmune blood disorder where there are insufficient platelets, leading to bruising and bleeding.
Q 2. Who should not use Tromlieva 25mg Tablet 7'S?
It is not recommended for children under one year with ITP, individuals with severe aplastic anemia, or those with hepatitis C.
Q 3. Will you be monitored during treatment?
Yes, regular monitoring of platelet levels, liver function, and eye health will be conducted.
Q 4. Can Tromlieva 25mg Tablet 7'S be taken on an empty stomach?
Yes, it should be taken on an empty stomach to avoid interference with absorption from dairy or supplements.
Q 5. What happens if you stop using Tromlieva 25mg Tablet 7'S?
Stopping suddenly can decrease platelet counts, potentially causing severe bleeding. Consult your doctor before discontinuing.
Fact Box of Tromlieva 25mg Tablet 7's
Molecule name: Eltrombopag
| Therapeutic class: Anticoagulant |
| Pharmacological class: Thrombopoietin (TPO) receptor agonist | Indications: 1. Low platelet counts caused by immune primary thrombocytopenia (ITP) or hepatitis C virus (HCV) infection. 2. Severe aplastic anaemia. |
References
- Novartis Pharmaceuticals UK Limited, Electronic medicines compendium (EMC), [ Revised on Jan 2022] [Accessed on 22 May 2023], https://www.medicines.org.uk/emc/files/pil.508.pdf
- GlaxoSmithKline, US Food and Drug Administration, [ Revised on October 2008] [Accessed on 22 May 2023], https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022291lbl.pdf
- Revolade, Annex I summary of Product Characteristics - European Medicines Agency. Available at: https://www.ema.europa.eu/en/documents/product-information/revolade-epar-product-information_en.pdf [Accessed on 22 May 2023].
Disclaimer
MrMed’s primary intention is to ensure that its consumers get information that is reviewed by experts, accurate and trustworthy. The information and contents of this website are for informational purposes only. They are not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please seek the advice of your doctor and discuss all your queries related to any disease or medicine. Do not disregard professional medical advice or delay in seeking it because of something you have read on MrMed. Our mission is to support, not replace, the doctor-patient relationship.
